Viewing data from:

VALTURNA

NDA

ALISKIREN HEMIFUMARATE; VALSARTAN | N022217 | NOVARTIS PHARMACEUTICALS CORP

2 strengths1 unique patent0 unique exclusivities

Patent Timeline

1 unique patent by expiration date

Expired (1)Today

Today

Jul. 3, 2026

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Approval Letters

8 letters from Drugs@FDA

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — EQ 150MG BASE;160MG

1 patent0 exclusivities▴

TABLET;ORAL | Approved: Sep 16, 2009

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
8168616	Jul 3, 2026	—	—	Yes	—	—

#002 — EQ 300MG BASE;320MG

1 patent0 exclusivities▾

TABLET;ORAL | Approved: Sep 16, 2009